MAM
Mediaedge:cia announces new European management team
MUMBAI: Mediaedge:cia has announced a new management team for Europe, Middle East and Africa.
Mark Austin will continue as chairman, Europe, Middle East and Africa, with Melanie Varley promoted to CEO, Europe, Middle East and Africa. They will report in to the agency’s global executive chairman Charles Courtier.
Austin and Varley will be based in the Europe, Middle East and Africa headquarters in London. Varley takes over from Dominic Grainger, who has now become GroupM Europe, Middle East and Africa managing director.
Austin and Varley have worked closely in the development of Mediaedge:cia globally and regionally since the company was launched in 2002. Their objective will be to further drive the growth and success of Mediaedge:cia across the Europe, Middle East and Africa region. Austin will focus primarily on Europe, Middle East and Africa strategy development, management of the local markets, mergers and acquisitions (including commercial development of MEC’s Interaction and Content businesses) and managing MEC’s talent to its full potential.
Varley’s task centres on the continued development of all European based clients and MEC product and services. She will play a key role in the management of the business’ specialist capabilities (such as Global Solutions, MEC Interaction and MEC Sponsorship).
Courtier was confident that this management team would continue to build on MEC’s success within the region. “I’m delighted with this partnership of Mark and Mel. They are both highly experienced operators within the industry and deeply committed to our vision of communications planning and implementation, Active engagement proposition and the role we play as a founding partner of GroupM,” he said.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
